This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Pearson, J. W. Articles by Torgersen, J. A. Search for Related Content PubMed PubMed Citation Articles by Pearson, J. W. Articles by Torgersen, J. A.

Drug Therapy against a Transplantable Guinea Pig Leukemia¹

Viral Biology Branch, National Cancer Institute, Bethesda 20014 [J. W. P., K. P., M. A. C.], and Flow Laboratories, Inc., Rockville 20852 [J. A. T.], Maryland

The effects of six clinically active drugs were tested against a transplantable leukemia in inbred strain 2 guinea pigs. Cytoxan and 6-mercaptopurine were found to elicit a therqeutic response against this leukemia based on complete tumor regression of the established tumor as well as a substantial increase in survival time. Animals dying in the untreated control and drug-treated groups revealed typical generalized lymphoblastic leukemia. However, only Cytoxan-treated animals that had relapsed exhibited central nervous system involvement originating from the arachnoid membrane.

A two-drug combination of Cytoxan and 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea was found not only to prevent meningeal leukemia development but also to result in "curing" all animals from their leukemia. This observation was based on a complete clinical, hematological, and histopathological "remission" period up to 176 days. The administration of 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea alone was observed not only to control the systemic leukemia but also to prevent central nervous system involvement. No relapses occurred after the first "remission" period was achieved in the groups of animals that received 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea.

¹ This work was supported in part by Contract 33391 within the Virus Cancer Program of the National Cancer Institute.

² Visiting Scientist, The Hebrew University of Jerusalem, Rehovat, Israel.

Received 9/16/74. Accepted 1/ 9/75.